- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted Therapy for Melanomas Without BRAF V600 Mutations
Authors
Keywords
-
Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 23, Issue 6, Pages 831-842
Publisher
Springer Science and Business Media LLC
Online
2022-04-05
DOI
10.1007/s11864-022-00946-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and Safety of Trametinib in Non‐V600 BRAF Mutant Melanoma: A Phase II Study
- (2021) Caroline A. Nebhan et al. ONCOLOGIST
- 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
- (2021) Paolo A. Ascierto et al. CLINICAL CANCER RESEARCH
- Molecular Markers and Targets in Melanoma
- (2021) Cristina Teixido et al. Cells
- CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
- (2021) Mattia Garutti et al. Cells
- LXH254, a potent and selective ARAF-sparing inhibitor of BRAF and CRAF for the treatment of MAPK-driven tumors
- (2020) Kelli-Ann Monaco et al. CLINICAL CANCER RESEARCH
- Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma
- (2019) Inês Pires da Silva et al. CLINICAL CANCER RESEARCH
- Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma
- (2019) Carla M.L. van Herpen et al. Oncotarget
- Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma
- (2019) Caroline Robert et al. EUROPEAN JOURNAL OF CANCER
- Targeting the MAPK Pathway in Advanced BRAF Wild-Type Melanoma
- (2019) R C Massa et al. ANNALS OF ONCOLOGY
- BRAF Mutation Class and Clinical Outcomes—Letter
- (2019) Matthew Dankner et al. CLINICAL CANCER RESEARCH
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations
- (2019) Christian Menzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanism of BRAF Activation Through Biochemical Characterization of the Recombinant Full-Length Protein
- (2018) Nicholas Cope et al. CHEMBIOCHEM
- Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanoma
- (2018) Matthew Dankner et al. CLINICAL CANCER RESEARCH
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
- (2018) Matthew Dankner et al. ONCOGENE
- Efficacy evaluation of imatinib for the treatment of melanoma: evidence from a retrospective study
- (2018) Xiaoting Wei et al. ONCOLOGY RESEARCH
- Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases
- (2018) Jonas Leichsenring et al. PATHOLOGY
- Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
- (2017) Dirk Schadendorf et al. EUROPEAN JOURNAL OF CANCER
- Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
- (2017) Reinhard Dummer et al. LANCET ONCOLOGY
- Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
- (2017) Zhan Yao et al. NATURE
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
- (2017) Ryan J. Sullivan et al. Cancer Discovery
- Clinicopathological features and clinical outcomes associated withTP53andBRAFNon-V600mutations in cutaneous melanoma patients
- (2016) Dae Won Kim et al. CANCER
- The molecular profile of metastatic melanoma in Australia
- (2016) Megan Lyle et al. PATHOLOGY
- Clinicopathological characteristics associated with BRAFK601Eand BRAFL597mutations in melanoma
- (2016) Mark Voskoboynik et al. Pigment Cell & Melanoma Research
- BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition
- (2015) Zhan Yao et al. CANCER CELL
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma
- (2014) Samantha E. Bowyer et al. MELANOMA RESEARCH
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice
- (2013) L Heinzerling et al. BRITISH JOURNAL OF CANCER
- Major Clinical Response to a BRAF Inhibitor in a Patient With a BRAF L597R–Mutated Melanoma
- (2013) Philippe Bahadoran et al. JOURNAL OF CLINICAL ONCOLOGY
- Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
- (2012) A. M. Menzies et al. CLINICAL CANCER RESEARCH
- BRAF inhibitor activity in V600R metastatic melanoma
- (2012) Oliver Klein et al. EUROPEAN JOURNAL OF CANCER
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
- (2012) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- BRAF L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors
- (2012) Kimberly Brown Dahlman et al. Cancer Discovery
- Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification
- (2011) Jun Guo et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma
- (2011) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis
- (2010) J.-H. Lee et al. BRITISH JOURNAL OF DERMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started